Fibroheal Woundcare Pvt Ltd, India’s pioneering silk-based wound care solutions provider, has raised ₹6.3 crore in its Pre-Series A funding round. The round saw participation from existing promoters and a group of new investors, including leading surgeons, medical professionals, and bankers. The company also received a commitment for an additional ₹10 crore from existing and new investors.
Founded in 2017 by Vivek Mishra and Bharat Tandon, and joined later by S. Subramanian, Fibroheal has been at the forefront of research-driven innovation in wound care, leveraging the healing potential of silk proteins. The funds raised will be used to scale the company’s go-to-market strategy, expand its team, and invest in a robust pipeline of medical devices.
Fibroheal’s unique silk-protein-based products are designed to heal various types of wounds, including diabetic ulcers, bed sores, post-operative wounds, and trauma injuries. Its product portfolio includes foams, mesh, powders, sprays, and adhesive dressings, which are currently used in over 500 hospitals across 19+ states. Fibroheal also maintains a strong e-commerce presence and has eight granted patents with several more in process.
Bharat Tandon, Co-Founder of Fibroheal and the lead investor in this round, said:
“Congratulations Vivek and whole team of Fibroheal on successful closure of your Pre-Series A Fundraise. As earliest backer of Fibroheal which is pioneer in medical application of Silk Proteins, I am happy to have led this round because I believe the product pipeline which the R&D team is working on is robust and extremely valuable with great potential. Good luck to the entire team.”
Dr. KK Narayanan, an investor with a track record of building successful ventures, said:
“Woundcare is a fast growing segment of the health and wellness sector. Fibroheal is poised to become a major player in this sector with a differentiated technology based on ‘Natural Silk,’ a committed leadership and a competent team.”
Joseph J. Thomas, Senior Director at India’s largest private bank, added:
“The medical devices and healthcare sector is in a very exciting place and there is exponential growth prospects in future. Fibroheal with its cutting-edge technology around silk proteins and various medical applications looks very promising.”
Dr. Abhishek Vijaykumar, a leading plastic and reconstructive surgeon, expressed his confidence:
“I have been using Fibroheal for about 4 years and the clinical outcome of their wound care products are excellent. They are value of money in comparison to existing imported products from various MNCs. I believe in Fibroheal’s strong and robust R&D pipeline and team. I believe in their CEO, Vivek Mishra, and his competent team to make it one of the leading players in the medical devices space in India and globally. Having watched Fibroheal for 4+ years, I am quite confident about this.”
Harikrishnan PV, CEO of KITVEN Fund, highlighted Fibroheal’s innovation and potential:
“KITVEN Fund 3 (Biotech) invested in Fibroheal Woundcare Pvt Ltd 1st in 2021 impressed by the potential and promising future in the woundcare industry using silk-derived proteins. True to our belief, Fibroheal has come a long way in developing unique products. Innovative use of silk-based products for wound healing is a groundbreaking approach exploring wound healing properties of Silk. The products made from silk have significant advantages over traditional treatments to meet growing demand of effective and affordable woundcare solutions especially for chronic wounds. Overall, Fibroheal is on right path and has potential to create huge impact globally with continued innovation, partnerships and association and we have confidence that company will continue to achieve substantial growth and success in future.”
Fibroheal has earned several accolades, including being a winner of the prestigious ELEVATE 100 program by the Karnataka government in 2019 and receiving the National Award for Technology Startup in 2020. The company has also collaborated with IISc Bangalore under the PMRF program to commercialize Fibroplug, a haemostatic product that has already treated over 3,000 bleeding cases within four months of its launch.
Backed by organizations such as BIRAC, CCAMP, and EXIM Bank’s “Ubharte Sitaare” Program, Fibroheal recently inaugurated a state-of-the-art integrated manufacturing plant and R&D center.
With a vision aligned with “Vocal for Local,” Fibroheal aims to leverage silk’s economic multiplier potential, healing millions of difficult-to-treat wounds globally while supporting the silk farming value chain.